Hepatitis C

Hepatitis C is a blood-borne virus that infects the liver, where it causes significant inflammation, damage and disruption of normal liver function. According to estimates by the World Health Organization, around 3 to 4 million people worldwide are infected with hepatitis C every year.
What is Hepatitis C?

Hepatitis C infection is a liver infection caused by the Hepatitis C virus. Infection with hepatitis C may damage the liver leading to chronic infection.

Read More

Overview

Feature Articles

Latest Hepatitis C News and Research

Scientific review highlights the impact of coffee on digestive organs

Scientific review highlights the impact of coffee on digestive organs

Study provides insights into how SARS-CoV-2 impacts the brain

Study provides insights into how SARS-CoV-2 impacts the brain

ASTRO provides new guidance on the use of external beam radiation therapy for primary liver cancers

ASTRO provides new guidance on the use of external beam radiation therapy for primary liver cancers

SARS-CoV-2 shown to spread through cell-to-cell transmission

SARS-CoV-2 shown to spread through cell-to-cell transmission

Bioinformatics pipeline can be used to quickly identify SARS-CoV-2 therapeutics

Bioinformatics pipeline can be used to quickly identify SARS-CoV-2 therapeutics

Analysis finds substantially more mutations in the omicron SARS-CoV-2 variant

Analysis finds substantially more mutations in the omicron SARS-CoV-2 variant

Characterization of the baseline SARS-CoV-2 S-reactive B cell repertoire

Characterization of the baseline SARS-CoV-2 S-reactive B cell repertoire

Interactions between RNA viruses and human RNA-binding proteins

Interactions between RNA viruses and human RNA-binding proteins

Direct-acting antivirals for HCV-related hepatocellular carcinoma reduces the risk of tumor progression

Direct-acting antivirals for HCV-related hepatocellular carcinoma reduces the risk of tumor progression

Liver cancer can be recognized by RNA fragments in saliva and blood

Liver cancer can be recognized by RNA fragments in saliva and blood

WHO’s C-TAP and MPP finalize licensing agreement with CSIC for COVID-19 serological antibody technology

WHO’s C-TAP and MPP finalize licensing agreement with CSIC for COVID-19 serological antibody technology

An increase in the half-life of remdesivir for COVID-19 treatment

An increase in the half-life of remdesivir for COVID-19 treatment

Oral SARS-CoV-2 Mpro inhibitor for therapeutic use

Oral SARS-CoV-2 Mpro inhibitor for therapeutic use

Curcumin, a bioactive component of turmeric, effectively neutralizes SARS-CoV-2 in vitro

Curcumin, a bioactive component of turmeric, effectively neutralizes SARS-CoV-2 in vitro

Study analyzes the financial burden of chronic hepatitis C on Ontario patients

Study analyzes the financial burden of chronic hepatitis C on Ontario patients

Study focuses on the high hepatitis C rates in pregnant people

Study focuses on the high hepatitis C rates in pregnant people

Chlorophyll catabolite pheophorbide A shows potential against SARS-CoV-2

Chlorophyll catabolite pheophorbide A shows potential against SARS-CoV-2

HCV treatment decreases protein activity levels involved in liver cirrhosis, research shows

HCV treatment decreases protein activity levels involved in liver cirrhosis, research shows

UQ start-up secures $1.3 million seed investment to develop new treatment for liver disease

UQ start-up secures $1.3 million seed investment to develop new treatment for liver disease

The biochemical mechanisms of remdesivir-mediated RNA synthesis inhibition

The biochemical mechanisms of remdesivir-mediated RNA synthesis inhibition